hero section gradient
11 handpicked stocks

Top Stocks for Recessions

These carefully selected stocks have shown remarkable resilience during economic downturns. Our team of professional analysts has identified companies that maintain stability when markets get shaky, giving you options for weathering financial storms.

Author avatar

Han Tan | Market Analyst

Published on May 3

Your Basket's Financial Footprint

Summary and investor takeaways for the provided market capitalisation breakdown.

Key Takeaways for Investors:
  • Large-cap dominance typically implies lower volatility and performance likely to broadly track major market indices.
  • Treat this basket as a core, long-term portfolio holding rather than a speculative growth allocation.
  • Expect steady, incremental appreciation over time; avoid anticipating explosive short-term gains.
Total Market Cap
  • GILD: $153.96B

  • PG: $354.86B

  • MDLZ: $79.90B

  • Other

About This Group of Stocks

1

Our Expert Thinking

When economic uncertainty looms, smart investors seek stability. These "Recession Proofers" have demonstrated resilience during previous downturns, providing steady performance even when markets struggle. They represent companies with business models designed to weather economic storms.

2

What You Need to Know

These companies come from sectors that typically maintain demand during recessions, such as discount retail, groceries, food and beverages, energy, utilities, and healthcare. Their steady revenue streams and proven stability can provide a safety net for your investment portfolio.

3

Why These Stocks

Each company in this group has been selected for its track record of resilience during economic contractions. They are industry leaders with robust business models, diversified revenue streams, and the ability to adapt to changing market conditions when times get tough.

Why You'll Want to Watch These Stocks

🛡️

Safety When It Matters Most

When markets get turbulent, these stocks have historically provided stability. They could be your portfolio's safeguard during economic uncertainty, potentially preserving value while others decline.

🔄

Recession-Resistant Revenue

These companies sell products and services people need regardless of economic conditions. While other businesses see declining sales during recessions, these tend to maintain steadier performance.

🧠

Smart Money Moves Here

Professional investors often shift toward these reliable performers when recession signals appear. Getting familiar with these stocks now could help you make informed decisions before everyone else catches on.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions